Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone781-674-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.88 million
Profitability
Miscellaneous
Employees255
OptionableOptionable
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) announced its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.04. The biotechnology company had revenue of $12.80 million for the quarter, compared to analysts' expectations of $10.76 million. View Agenus' Earnings History.
When is Agenus' next earnings date?
Has Agenus been receiving favorable news coverage?
Media coverage about AGEN stock has trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agenus earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the next several days.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Atara Biotherapeutics (ATRA), Spark Therapeutics (ONCE), Regenxbio (RGNX), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB) and Novavax (NVAX).
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
- Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)
- Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
- Dr. Robert B. Stein, Sr. R&D Advisor (Age 68)
- Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
Who are Agenus' major shareholders?
Agenus' stock is owned by a number of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.03%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Corp Incyte, Garo H Armen and Karen Valentine. View Institutional Ownership Trends for Agenus.
Which major investors are selling Agenus stock?
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $3.67.
How big of a company is Agenus?
Agenus has a market capitalization of $447.58 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.
What is Agenus' official website?
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (NASDAQ AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
